Pharmacogenetic Considerations in Beta-Blocker Therapy
DOI:
https://doi.org/10.69734/hpaezm84Keywords:
Pharmacogenetic , beta-blocker, CPIC, cyp450, ADRB2, ADRA2C, GRK5, CYP2D6Abstract
Pharmacogenetic testing offers a promising approach to personalizing beta-blocker therapy which is used for a variety of diseases, such as heart failure, myocardial infarction and migraine prophylaxis. The genetic variability in the metabolism and response to beta-blockers such as metoprolol can significantly influence treatment outcomes. Understanding these genetic differences can help optimize therapy and minimize adverse effects. A brief summary of the current guideline and recommendations:
- Approximately 0.3-6.5% (depending on their ancestry) of patients are CYP2D6 poor metabolizers.
- CYP2D6 Poor Metabolizers have significantly decreased metabolism of metoprolol, leading to increased drug concentration and a higher risk of adverse effects.
- The highest dose of metoprolol that patients can tolerate may be lower in CYP2D6 poor metabolizers compared to those that are non-poor CYP2D6 metabolizers.
- Current evidence is insufficient to support routine clinical testing or therapeutic adjustments for other genes affecting beta-blocker pharmacodynamics, such as ADRB1, ADRB2, ADRA2C, and GRK5.
- Future research should consider the combined effects of multiple genetic variants (e.g., polygenic risk scores) rather than focusing solely on single-gene associations.
References
(FDA) USFaDA. Table of Pharmacogenetic Associations: FDA; 2024 [Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations.
(FDA) USFaDA. Table of Pharmacogenomic Biomarkers in Drug Labeling: f'da; 2024 [Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017;102(3):502-10.
Duarte JD, Thomas CD, Lee CR, Huddart R, Agundez JAG, Baye JF, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clin Pharmacol Ther. 2024.
Fayed MS, Saleh MA, Sabri NA, Elkholy AA. β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome. Future Sci OA. 2023;9(10):Fso895.
Terra SG, Hamilton KK, Pauly DF, Lee CR, Herbert Patterson J, Adams KF, et al. β1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenetics and Genomics. 2005;15(4):227-34.
Perez JM, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Medicine. 2003;9(10):1300-5.
de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, Foucher-Hossein C, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005;15(3):137-42.
Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288-93.
Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33(32):9414-9.
Metra M, Covolo L, Pezzali N, Zacà V, Bugatti S, Lombardi C, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010;24(1):49-60.
Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: A literature review. J Int Med Res. 2016;44(1):15-29.
Aharon DA, Friedman EG, Overbey JR, McLaughlin M, Langaee T, Thurston RC. The association of an alpha2C adrenoreceptor gene polymorphism with vasomotor symptoms in African American women. Menopause. 2019;26(3):300-5.
Kurnik D, Cunningham AJ, Sofowora GG, Kohli U, Li C, Friedman EA, et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009;10(10):1581-7.
Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14(5):510-7.
Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27(6):874-87.
Dean L. Metoprolol Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
Meloche M, Khazaka M, Kassem I, Barhdadi A, Dubé MP, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. Br J Clin Pharmacol. 2020;86(6):1015-33.
Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther. 2009;85(3):269-72.
CYP2D6 Allele Frequency Table [Internet]. CPIC. 2024 [cited 7/15/2024]. Available from: https://files.cpicpgx.org/data/report/current/frequency/CYP2D6_frequency_table.xlsx.
Cicali EJ, Elchynski AL, Cook KJ, Houder JT, Thomas CD, Smith DM, et al. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clin Pharmacol Ther. 2021;110(3):677-87.
Lanfear DE, Luzum J, She R, Gui H, Donahue MP, O'Connor CM, et al. Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. Circulation: Heart Failure. 2020;13(12):E007012.
Lanfear DE, Luzum J, She R, Li J, Sabbah HN, Zeld N, et al. Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients with Heart Failure Using the United Kingdom Biobank. Circulation: Genomic and Precision Medicine. 2023;16(2):E003835.
Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, Antúnez-Rodríguez A, Pozo-Agundo A, Moreno-Escobar E, et al. Pharmacogenetic polymorphisms affecting bisoprolol response. Biomedicine & Pharmacotherapy. 2021;142:112069.
Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel). 2020;11(11).
Wang Z, Wang L, Xu RA, Zhan YY, Huang CK, Dai DP, et al. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016;10:1909-16.
Howrie DL, Venkataramanan R. Pharmacogenomics: A Pathway to Individualized Medicine. In: Da Cruz EM, Ivy D, Jaggers J, editors. Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. London: Springer London; 2014. p. 981-7.
Khatri R, Fallon JK, Sykes C, Kulick N, Rementer RJB, Miner TA, et al. Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. Front Pharmacol. 2021;12:655320.
Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther. 2006;31(1):99-109.
Kilford P, Khoshaein N, Southall R, Gardner I. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics. 2022;47(5):699-710.
Lee YJ, Byeon JY, Kim SH, Kim YH. Cyp2d6 Genetic Polymorphism Has Significant Effects on The Pharmacokinetics of Propranolol. Clinical Therapeutics. 2015;37(8, Supplement):e139.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information